Heart failure recovery: could patients finally take fewer pills?

NCT ID NCT07513883

Recruiting now Disease control Sponsor: Ziekenhuis Oost-Limburg Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study looks at whether people whose heart failure has improved can safely cut back on some of their daily medications. Participants will either continue all four standard drugs or gradually reduce to just two under close monitoring. The goal is to see if heart function stays stable over two years, using heart scans and blood tests.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: down-titration of heart failure medications (SGLT2 inhibitor, mineralocorticoid receptor antagonist, and switching ARNI to ACE inhibitor or ARB)
What this could lead to: If successful, this could show that some heart failure patients in remission can safely take fewer medications, reducing side effects and costs.
What could go wrong: This is a small pilot study (100 people) and may not prove safety or effectiveness. Reducing medications could risk heart function worsening or hospitalization.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HEART FAILURE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

heart failure systolic heart failure

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HEART FAILURE

Contacts and locations

Locations

Ziekenhuis Oost-Limburg
RECRUITING

Genk, 3600, Belgium

More trials for these conditions

Other studies related to the condition(s) this trial covers.